Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.
复制标题

Perfect ALKemy：优化 ALK 导向疗法在肺癌中的使用。

DOI：
10.1158/1078-0432.ccr-14-2306
复制
发表时间：
2014
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
通讯作者：
Gettinger,Scott
Gettinger,Scott
中科院分区：
--
文献类型：
--
作者：
Politi,Katerina;Gettinger,Scott

文献摘要

相似文献

ALK突变是ALK重排肺癌中小分子ALK抑制剂获得性耐药的常见机制。不同的突变体对ALK抑制剂表现出不同的敏感性。将肿瘤的突变谱与适当的ALK抑制剂相匹配对于患者的最大益处可能是重要的.Clin Cancer Res; 20（22）; 5576-8.©2014 AACR.
Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.Clin Cancer Res; 20(22); 5576–8. ©2014 AACR.